Padcev, Keytruda, and Balversa leave little room for Opdivo in urothelial carcinoma

Badder cancer is highly prevalent in the developed world and is the sixth most common cancer diagnosis.

The average five-year survival rate in the US is 77%, but this number drops to 5% for patients with metastatic disease.